Biofrontera Q3 revenue up 30% driven by new Ameluz cancer approval
Biofrontera reported Q3 2026 revenue of $9.1 million, up 30% year-over-year, following U.S. FDA approval for Ameluz to treat cancerous skin tumors and a ruling clearing its imported devices from ITC sanctions.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed